NPS views partnerships as an important component of our corporate strategy. We collaborate to manage risk and accelerate the development and commercialization of our product candidates. We have a portfolio of licensed compounds that includes agreements with Amgen, Kyowa Kirin, and Nycomed.
| Program | Indication | Market/Partner | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|---|---|---|
| Sensipar (cinacalcet HCl) | Secondary Hyperparathyroidism | Worldwide excluding Asia/Amgen | |||||
| Sensipar (cinacalcet HCl) | Hypercalcemia in Parathyroid Cancer | Worldwide excluding Asia/Amgen | |||||
| Regpara (cinacalcet HCl) | Secondary Hyperparathyroidism | Asia/Kyowa Kirin | |||||
| Preotact (parathyroid hormone 1-84 [rDNA origin] injection) | Osteoporosis | Ex-U.S./Nycomed | |||||
| Teduglutide | Short Bowel Syndrome | Ex-N. America/Nycomed | |||||
| Cinacalcet HCl | Primary Hyperparathyroidism | Worldwide excluding Asia/Amgen |